Developing Next-Generation Activated Protein C for Human Therapeutic Use
ZZ Biotech, LLC - Developing Innovative Biologic Treatments
ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. ZZ Biotech was incepted in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute.
ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke, other neurological diseases, and diabetic foot ulcers. ZZ Biotech was incepted in 2006 to focus on the development of 3K3A-APC.
ZZ Biotech has completed RHAPSODY, a Phase 2 clinical study in patients with moderate to severe ischemic stroke.
FOOT ULCER PROGRAM
APC and 3K3A-APC have shown efficacy in several in vitro and in vivo wound healing studies. APC has also been studied in multiple human clinical wound healing studies, including a foot ulcer study.